Study shows reliability and robustness of injectable anti-obesity medication
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and other settings. The study is published today in the
Journal of the American Medical Association.
The 68-week study was conducted at 41 sites in the United States from August 2018 to April 2020 and was designed to boost total weight loss with semaglutide by combining the medication with a more intensive diet and physical activity program than what was used in the STEP 1 trial, published online February 10th in the
By Travis Cleven
Feb 25, 2021 4:54 AM
Denise Ney is a Professor at UW-Madison in the Department of Nutritional Sciences and sheâs kept very busy while being there. For the past 15 years, sheâs been studying a protein found in sweet cheese whey called Glycomacropeptide (GMP). Going back to the beginning, Ney was invited to do research on GMP by some dietitians and physicians at the Waisman Center in Madison. They wanted her to help them bring to life the idea of making GMP a dietary supplement for people with a rare genetic disease called Phenylketonuria (PKU).
First of all, PKU is a genetically inherited disease thatâs transferred to the baby if both parents carry one gene for the disease. Even though the parents carry the disease, they donât have it themselves. The other tricky part is that you arenât able to tell if the baby has it unless they get tested at birth, which the U.S. has been doing for a while now. Ney said that in Wisconsin we have f
UW Professor Uses Dairy To Fight Genetic Disease And More wxerfm.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wxerfm.com Daily Mail and Mail on Sunday newspapers.
E-Mail
PHILADELPHIA A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and other settings. The study is published today in the
Journal of the American Medical Association.
The 68-week study was conducted at 41 sites in the United States from August 2018 to April 2020 and was designed to boost total weight loss with semaglutide by combining the medication with a more intensive diet and physical activity program than what was used in the STEP 1 trial, published online February 10th in the
Yoojin Lee studied food science and engineering in South Korea. A growing interest in how nutrients affect the body led her to the Department of Nutritional Sciences in the College of Agriculture, Health and Natural Resources where her research focused on the relationship between obesity-associated diseases and foods that might have protective effects and other positive health benefits.
Obesity, a state caused by an imbalance between energy intake and expenditure, is an established risk factor for non-alcoholic fatty liver disease (NAFLD). NAFLD refers to a range of conditions concerning the accumulation of excess fat in the liver of people who drink little or no alcohol. There is an increasing prevalence of NAFLD. It is estimated to be the most common liver disease in the world and affects 80 to 100 million in the US alone. With the obesity rate of US adults recently found to be 42 percent, the impacts of health are far-reaching.